Clinical review highlights diagnostic variability of interstitial lung disease in cancer patients, indicating a need for standardized risk stratification during checkpoint inhibitor therapy.
Extract Immune checkpoint inhibitors (ICIs) are immunomodulatory monoclonal antibodies that enhance T-cell-mediated cytotoxicity and have significantly transformed the treatment and outcomes of many cancers [1]. The primary targets of checkpoint inhibition are programmed cell death receptor 1 (PD-1), its ligand programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) [2]. Shareable abstract A standardised risk assessment before initiating ICI treatment may improve early detection and management of IR-ILD. Multidisciplinary collaboration is crucial for enhancing patient safety, improving treatment outcomes and advancing research. https://bit.ly/4qAthl6
No takes yet. Share an insight, caveat, or question.
Fabbri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: